As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Alzheimer’s Disease Package


> Download your free sample           > Contact us to find out more


This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 133 high prescribing neurologists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Neurologists 32 22 18 15 16 15 15


Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–21
Patient subpopulations forecasted
  • Mild cognitive impairment due to Alzheimer’s disease
  • Mild Alzheimer’s disease
  • Moderate Alzheimer’s disease
  • Severe Alzheimer’s disease
Drugs profiled
  • Aricept
  • Exelon
  • Namenda/Ebixa
  • Razadyne/Reminyl
  • EVP-6124
  • Gammagard
  • LMTX
  • Lu AE58054
  • SB-742457
  • Solanezumab



Key Findings

Over the course of 2012–21, the market for drugs with established modes of action, such as acetylcholinesterase inhibition and NMDA receptor antagonism, will remain relatively flat. The beta amyloid immunotherapy solanezumab (Eli Lilly), expected to launch from 2018, has the potential to grow the market by $4.6bn. Datamonitor Healthcare forecasts that around 330,000 patients with mild cognitive impairment or mild Alzheimer’s disease will receive immunotherapies annually by 2021 in the US, Japan, and five major EU markets.

> Download your free sample           > Contact us to find out more

Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726